News

NEWS

Versatope Speaking Engagements - 2024

Microbial nano-vesicles Derived from Probiotic Cell Lines for Drug and Vaccine Delivery

Institute of Medical Sciences, University of Aberdeen 

Aberdeen, Scotland, UK,  June 4, 2024

Vaccine and Therapeutic Delivery with Recombinant Nanovesicles

Formulation UK 2024 Congress, Oxford Global Conferences

Hammersmith, London, United Kingdom April 25, 2024

Versatope Speaking Engagements - 2023

Transformational Vaccines and Therapeutics with Recombinant Extracellular Vesicles

6th Annual Cell & Gene Therapy Innovation Leaders Summit 2023

Berlin, February 15, 2023

Versatope Speaking Engagements - 2022

Placing Patients at the Center  - Panel Discussion

Longwood Healthcare Leaders Fall Conference

Boston, September 21, 2022

Therapeutic Delivery with Recombinant Nano-Vesicles

Vector Development for Cell and Gene Therapy Summit

Boston, August 25, 2022

Accelerating Outer Membrane Vesicle Vaccines Towards the Clinic

 Drug Target Review Summit - Development of Next-Generation Vaccines Summit

Online Summit, June 9, 2022

Designing Potent Immunotherapies and Vaccines with the Power of ROMV's (recombinant outer membrane vesicles)

Applications of Exosomes: Meet the Exosome, the Rising Star in Drug Delivery

Digital Event, March 30, 2022

VERSATOPE IN THE NEWS

Versatope Launches Clinical Development Team for VT-105, a Pan-influenza A Vaccine Candidate

LOWELL, Mass., Sept. 11, 2024  Versatope Therapeutics Incorporated announced today their new Chief Medical Officer, Dr. M.P. Anza Mammen, MD and the addition of their Chairman of the Scientific Advisory Board, Dr. Robert B. Belshe.

Link to Article

Advancing Vaccines with Extracellular Vesicles


September  27, 2022   Dr. Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles.

Link to Article

Versatope Expands Scientific Advisory Board with Dr. Drew Weissman and Board of Directors with Dr. James Kuo and Jeremy Gowler

LOWELL, Mass., Oct. 14, 2021 Versatope announced today that Dr. Drew Weissman, a leading mRNA vaccine expert, joined their Scientific Advisory Board. Separately, Dr. James Kuo and Jeremy Gowler joined the company's Board of Directors to diversify their pipeline and expand their business development activities.

Press Release
Versatope Awarded Grant for 
Novel C. diff Vaccine 

LOWELL, Mass., Sept. 9, 2020 / Versatope announced that it has been awarded a Phase 1 Small Business and Innovation Award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) to develop a novel vaccine for the prevention and possible treatment for Clostridioides difficile, also known as C. diff.
Press Release

Clostridium difficile bacteria, 3D illustration.  Photo: Kateryna Kon / Shutterstock


May 6, 2020 - Versatope featured on Boston 25 News in a story featuring companies at UMass Lowell's M2D2 who are working on innovative solutions for COVID-19.
Versatope Selects Influenza Vaccine Candidate for Clinical Development

LOWELL, Mass., March 18, 2020 / Versatope announced today the selection of a universal influenza vaccine candidate for clinical development using recombinant outer membrane vesicles (rOMVs), combining diverse variants of influenza strains on a single nano-sized rOMV that may provide better cross-strain protection than influenza vaccines composed of individual strains. 
Press Release

Versatope Aims to Develop Coronavirus Vaccine
March 30, 2020, UMASS M2D2's Resident Start-Up Biotech Company, Versatope Therapeutics is designing a COVID-19 vaccine 

March 13, 2020, Versatope CEO Christopher Locher talks about the company’s potential to develop a vaccine for the SARS-2 coronavirus (Covid-19).  By Elizabeth Dobbins, Lowell Sun.  Photo Credit: Julia Malakie, Lowell Sun. Read Article

Scientific Advisory Board Members Join Versatope Therapeutics Team
LOWELL, Mass., Jan. 28, 2020  Versatope Therapeutics, Inc., a biotechnology company developing vaccines and therapeutics, announced today four new members to their Scientific Advisory Board (SAB) who are leaders in the field infectious disease research and influenza vaccines: Drs. Frederick G. Hayden, Stacey Schultz-Cherry, David Topham and Ralph Tripp. View Press Release

Versatope Named One of  Top University Spin Offs by Venture Radar


November 18, 2019
Venture Radar has selected Versatope as a Top University Spin-Off Company that could have the biggest commercial impact. Read More

Versatope CEO Discusses Company's Progress on Universal Flu Vaccine
 
Oct 16, 2019 
Versatope CEO, Dr. Christopher Locher sits down with Biospace's Alex Keown to discusses the urgent need for a universal flu vaccine and the company's progress toward that goal using recombinant outer membrane vesicles (rOMV).  Link to Article

Inside One Lowell Startup's Quest to Create a Universal Flu Vaccine 

Versatope Therapeutics Receives Funding from the National Institutes of Health 
to Develop its Universal Influenza Vaccine.  
LOWELL, Mass., September 25, 2019 – Versatope Therapeutics, Inc., a biotechnology company developing vaccines and
therapeutics, announced today that it has been awarded a contract with National Institute of Allergy and Infectious
Diseases (NIAID), a division of the National Institutes of Health (NIH) worth up to $17.9M over five years. The award is
through the Broad Agency Announcement (BAA) program to advance Versatope’s universal influenza vaccine candidate.  

The NIAID contract will support Versatope's goal of producing an influenza vaccine designed to protect against multiple strains using extracellular bacterial vesicles. NIAID funding will support manufacturing, stability and human clinical studies to demonstrate safety and tolerability in healthy volunteers.

"The support from NIAID will advance Versatope's goal of developing a novel universal influenza vaccine and creating new biotechnology jobs in Lowell, Massachusetts," said Christopher Locher, Ph.D., CEO of Versatope Therapeutics, Inc. "This is a big advance for our program toward clinical studies and commercialization."     View Press Release

Versatope receives award funding through Massachusetts Life Sciences Center (MLSC) Milestone Achievement Program (MAP) for developing vaccine technology
  September 4, 2019 – Versatope Therapeutics, Inc., receives Massachusetts Life Sciences Center (MLSC) funding to support Versatope’s effort to develop a universal influenza vaccine that has the potential to provide robust and durable immunity against multiple influenza. The funding is through the MLSC’s Milestone Achievement Program (MAP), which addresses the needs of early-stage life sciences companies by providing grant funding to execute critical, value-creating technical milestones. Versatope will create a traceable microbial cell line for master cell banking and establish a reproducible and consistent manufacturing process. These activities are critical to the manufacturing and quality control process for a vaccine product.   View Press Release
Versatope Therapeutics Wins Second Prize at the Future of Medicine Pitch Competition 
Sponsored by Takeda Pharmaceuticals
April 11, 2019Versatope Therapeutics, Inc., received the second prize at the Cambridge Innovation Center Venture Cafe's Future of Medicine Pitch Competition sponsored by Takeda Pharmaceuticals. Winners will travel to Japan to visit Takeda's Shonan iPark, an incubator and accelerator for cutting edge biotech research. 

Dr. Toshio Fujimoto, General Manager of Takeda's Shonan iPark presents the award to Christopher Locher, CEO and Founder of Versatope Therapeutics.

MORE NEWS and ARTICLES

Share by: